Premenopausal serum androgens and breast cancer risk: a nested case-control study
Authors:
- Anne Zeleniuch-JacquotteAZAnne Zeleniuch-Jacquotte
- Yelena AfanasyevaYAYelena Afanasyeva
- Rudolf KaaksRKRudolf Kaaks
- Sabina RinaldiSRSabina Rinaldi
- Stephanie ScarmoSSStephanie Scarmo
- Mengling LiuMLMengling Liu
- Alan A ArslanAAAlan A Arslan
- Paolo TonioloPTPaolo Toniolo
- Roy E ShoreRSRoy E Shore
- Karen L KoenigKKKaren L Koenig
Open Access
- 16 February 2012
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , 1-12
Abstract
Introduction: Prospective epidemiologic studies have consistently shown that levels of circulating androgens in postmenopausal women are positively associated with breast cancer risk. However, data in premenopausal women are limited. Methods: A case-control study nested within the New York University Women's Health Study was conducted. A total of 356 cases (276 invasive and 80 in situ) and 683 individually-matched controls were included. Matching variables included age and date, phase, and day of menstrual cycle at blood donation. Testosterone, androstenedione, dehydroandrosterone sulfate (DHEAS) and sex hormone-binding globulin (SHBG) were measured using direct immunoassays. Free testosterone was calculated. Results: Premenopausal serum testosterone and free testosterone concentrations were positively associated with breast cancer risk. In models adjusted for known risk factors of breast cancer, the odds ratios for increasing quintiles of testosterone were 1.0 (reference), 1.5 (95% confidence interval (CI), 0.9 to 2.3), 1.2 (95% CI, 0.7 to 1.9), 1.4 (95% CI, 0.9 to 2.3) and 1.8 (95% CI, 1.1 to 2.9; Ptrend = 0.04), and for free testosterone were 1.0 (reference), 1.2 (95% CI, 0.7 to 1.8), 1.5 (95% CI, 0.9 to 2.3), 1.5 (95% CI, 0.9 to 2.3), and 1.8 (95% CI, 1.1 to 2.8, Ptrend = 0.01). A marginally significant positive association was observed with androstenedione (P = 0.07), but no association with DHEAS or SHBG. Results were consistent in analyses stratified by tumor type (invasive, in situ), estrogen receptor status, age at blood donation, and menopausal status at diagnosis. Intra-class correlation coefficients for samples collected from 0.8 to 5.3 years apart (median 2 years) in 138 cases and 268 controls were greater than 0.7 for all biomarkers except for androstenedione (0.57 in controls). Conclusions: Premenopausal concentrations of testosterone and free testosterone are associated with breast cancer risk. Testosterone and free testosterone measurements are also highly reliable (that is, a single measurement is reflective of a woman's average level over time). Results from other prospective studies are consistent with our results. The impact of including testosterone or free testosterone in breast cancer risk prediction models for women between the ages of 40 and 50 years should be assessed. Improving risk prediction models for this age group could help decision making regarding both screening and chemoprevention of breast cancer.Keywords
This publication has 64 references indexed in Scilit:
- Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast CancersJNCI: Journal of the National Cancer Institute, 2011
- Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography–tandem mass spectrometrySteroids, 2011
- Analysis of estrogens in serum and plasma from postmenopausal women: Past present, and futureSteroids, 2010
- Mammary gland and endometrial effects of testosterone in combination with oral estradiol and progesteroneMenopause, 2009
- Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET CohortCancer Epidemiology, Biomarkers & Prevention, 2009
- The Role of Androgens in Normal and Malignant Breast TissueBreast Care, 2008
- Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health StudyBreast Cancer Research, 2008
- Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC)JNCI: Journal of the National Cancer Institute, 2005
- Endogenous sex hormones and subsequent breast cancer in premenopausal womenInternational Journal of Cancer, 2004
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989